CD135

Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting

Retrieved on: 
Friday, June 11, 2021
Chemical compounds, Tyrosine kinase receptors, Protein kinase inhibitors, Organic compounds, AXL receptor tyrosine kinase, Heterocyclic compounds, Bemcentinib, Orphan drugs, CD135, Midostaurin

An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.

Key Points: 
  • An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.
  • The data indicate that the combination of bemcentinib, a once-daily oral AXL-inhibitor and LDAC is efficacious and well tolerated in the elderly and unfit relapsed AML population.
  • Ongoing dialogue continues with the FDA and EMA regulatory agenciesto align on a pathway for apivotalregistration trial for the combination ofbemcentinibandLDAC in relapsed elderly AML patients unfit for intensive chemotherapy.
  • Data from a Phase II in human clinical trial has shown that treatment with AXL inhibitor bemcentinib increased the rate ventilator free survival in hospitalised COVID-19 patients.

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

Retrieved on: 
Monday, June 7, 2021
Tyrosine kinase receptors, CD135, Midostaurin

IND clearance by the FDA paves the way to test a differentiated treatment approach by targeting extracellular FLT3, an oncogenic driver in AML, stated Patrick Baeuerle, Cullinans Chief Scientific Officer, Biologics.

Key Points: 
  • IND clearance by the FDA paves the way to test a differentiated treatment approach by targeting extracellular FLT3, an oncogenic driver in AML, stated Patrick Baeuerle, Cullinans Chief Scientific Officer, Biologics.
  • We are excited to initiate human dosing of CLN-049, a T cell-engaging, IgG-like antibody in patients with relapsed/refractory AML.
  • CLN-049is a humanized bispecific antibody being developed for relapsed/refractory AML.
  • In preclinical studies, CLN-049led to potent FLT3-dependent killing of leukemic cellsin vitroat a wide range of FLT3 expression levels on AML cells.

Aptose to Hold Corporate Update Friday, June 11th

Retrieved on: 
Thursday, May 27, 2021
Enzymes, Branches of biology, Tyrosine kinases, CD135, Acute myeloid leukemia, Cell signaling, Myelodysplastic syndrome, Bruton's tyrosine kinase, Protein kinase inhibitors, Antibody-drug conjugates, Midostaurin, Devimistat

SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.

Key Points: 
  • SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.
  • The event will include an up-to-date review of clinical data available for Aptoses clinical programs: luxeptinib (CG-806), Aptoses oral, first-in-class FLT3 and BTK kinase inhibitor in two Phase 1 a/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies; and APTO-253, a first-in-class small molecule MYC repressor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndromes (MDS).

Kronos Bio Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 26, 2021
Enzymes, Tyrosine kinase inhibitors, Chemical compounds, Entospletinib, Indazoles, Morpholines, Tyrosine kinase receptors, Tyrosine kinases, Branches of biology, CD135, Tyrosine-protein kinase SYK, Acute myeloid leukemia

The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .

Key Points: 
  • The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .
  • Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • Kronos Bio is developing a portfolio of spleen tyrosine kinase (SYK) inhibitors, entospletinib (ENTO) and lanraplenib (LANRA), for the treatment of NPM1-mutated and FLT3-mutated acute myeloid leukemia (AML).
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.

Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 20, 2021
Chemical compounds, Clinical medicine, Cancer, Lactams, PLK1, Protein kinase inhibitors, Acute myeloid leukemia, Decitabine, Chemotherapy, CD135, Bemcentinib

Our goal is to overcome resistance, improve response to treatment and increase overall survival.

Key Points: 
  • Our goal is to overcome resistance, improve response to treatment and increase overall survival.
  • We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
  • Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment.
  • A Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML) completed enrollment in 2020.

Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021  

Retrieved on: 
Monday, April 26, 2021
Clinical medicine, Medicine, CD135, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Leukemia, Protein kinase inhibitors, Lactams, Phosphoinositide 3-kinase inhibitor, Toralizumab

b"The live conference call can also be accessed through a link on the Investor Relations section of Aptose\xe2\x80\x99s website at https://www.aptose.com/investors/news - events/ir - calendar .

Key Points: 
  • b"The live conference call can also be accessed through a link on the Investor Relations section of Aptose\xe2\x80\x99s website at https://www.aptose.com/investors/news - events/ir - calendar .
  • An archived version of the webcast along with a transcript will be available on the company\xe2\x80\x99s website for 30 days.\nThe press release, the financial statements and the management\xe2\x80\x99s discussion and analysis for the year and quarter ended March 31, 2021 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml .\nAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.
  • The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
  • The Company has two clinical- stage investigational products for hematologic malignancies: luxeptinib (formerly CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).\n"

Acute Myeloid Leukemia (AML): Utilizing Single-Cell Multi-Omics to Uncover its Evolution and Resistance Mechanisms, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, April 21, 2021
Chemical compounds, Organic compounds, Chemistry, Tyrosine kinase receptors, CD135, Tyrosine kinase inhibitors, Piperidines, Morpholines, Quizartinib, Gilteritinib, Acute myeloid leukemia, Leukemia

b'TORONTO, April 21, 2021 /PRNewswire-PRWeb/ --Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy characterized by the overproduction of abnormal myeloblasts.

Key Points: 
  • b'TORONTO, April 21, 2021 /PRNewswire-PRWeb/ --Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy characterized by the overproduction of abnormal myeloblasts.
  • For patients with FLT3 mutated AML, the FLT3 inhibitors (FLT3i), gilteritinib and quizartinib, can improve patient outcomes.\nHowever, the development of secondary resistance to these drugs remains a major challenge.
  • The acquisition of new mutations and the emergence of new subclones during the course of therapy can drive relapse.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.\nSydney Perelmutter, Xtalks, +1 (416) 977-6555 x 352, [email protected]\n'

Global Acute Myeloid Leukemia (AML) Disease Market Report 2021 Featuring Apollomics, Astellas, BerGenBio, Chimerix, Daiichi Sankyo, Forma, GlycoMimetics, Kiadis, MacroGenics, Medigene & Piramal

Retrieved on: 
Wednesday, April 14, 2021
Chemical compounds, Lactams, Organic compounds, Heterocyclic compounds, Nucleosides, Triazines, Orphan drugs, Tyrosine kinase receptors, CD135, Devimistat, Decitabine, Azacitidine

"Acute" means that the leukemia may progress rapidly - AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including the lymph nodes, spleen, central nervous system, and testicles.\nRelapsed/refractory AML remains an area of unmet need, and new therapies are being developed.

Key Points: 
  • "Acute" means that the leukemia may progress rapidly - AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including the lymph nodes, spleen, central nervous system, and testicles.\nRelapsed/refractory AML remains an area of unmet need, and new therapies are being developed.
  • Not including FLT3 or IDH inhibitors, there are currently five late-stage therapies being evaluated for this setting (devimistat, DFP-10917, flotetuzumab, Iomab-B, and uproleselan).\nKey recent events include the approval of Onureg and presentation of numerical data from Venclexta\'s VIALE-A trial.
  • There were Phase III failures for Helsinn\'s pracinostat combined with azacitidine in the newly diagnosed setting and for Roche\'s idasanutlin and Otsuka\'s guadecitabine in the relapsed/refractory setting.
  • AML drugs, on average, take 10.8 years from Phase I to approval, compared to 9.6 years in the overall oncology space.\n'

Ascentage Pharma Releases Preclinical Data of Its Core Drug Candidates at AACR Annual Meeting 2021, with Results Signifying the Potential of Multiple Combination Therapies in Cancer

Retrieved on: 
Tuesday, April 13, 2021
Branches of biology, Tyrosine kinase receptors, Cell biology, Oncogenes, CD135, Apoptosis, Programmed cell death, Bcl-2

These studies are from seven preclinical studies in various tumor types and have signified the therapeutic potential of multiple combination therapies in cancer.\nThe AACR annual meeting is one of the world\'s largest and long-standing scientific gatherings in the field of cancer research.

Key Points: 
  • These studies are from seven preclinical studies in various tumor types and have signified the therapeutic potential of multiple combination therapies in cancer.\nThe AACR annual meeting is one of the world\'s largest and long-standing scientific gatherings in the field of cancer research.
  • We will strive to make more progress of our core drug candidates and to hopefully bring these potential therapeutics to patients as early as possible.
  • Despite antitumor effects of selective FLT3 inhibitors, resistance to these agents continues to pose a formidable clinical challenge.
  • The expression of pro-survival protein BCL-2 is frequently dysregulated, conferring resistance to FLT3 inhibitors, in AML.

Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021

Retrieved on: 
Saturday, April 10, 2021
Tyrosine kinase receptors, Cancer immunotherapy, CD135, American Association for Cancer Research, FLT3LG, Immunotherapy

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.
  • ET through the virtual meeting website at www.aacr.org and on the Harpoon corporate website at www.harpoontx.com .
  • Data show that FLT3 TriTACs bind human and non-human primate FLT3, and can redirect T cells to kill FLT3 expressing cells in vitro.
  • These forward-looking statements are based on Harpoon Therapeutics expectations and assumptions as of the date of this press release.